Delamanid
drugOn this page
Also known as DeltybaOpc 67683OPC-67683OPC67683SID174006644MMV688262
Summary
Delamanid (CHEMBL218650) is an approved small molecule (ATC J04AK06); indicated across 4 conditions including multidrug-resistant tuberculosis and tuberculosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J04AK06
- Indications: 4 conditions
- Clinical trials: 28
- Chemistry: 534.5 Da · C25H25F3N4O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL218650 |
| Name | Delamanid |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 6480466 |
| ATC | J04AK06 |
| Molecular formula | C25H25F3N4O6 |
| Molecular weight | 534.5 |
| InChIKey | XDAOLTSRNUSPPH-XMMPIXPASA-N |
SMILES: C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F
IUPAC name: (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole
Also known as: Delamanid, Deltyba, Opc 67683, OPC-67683, OPC67683, DELAMANID, SID174006644, MMV688262, delamanid
Patent coverage: 309 distinct patent families (654 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| SLC6A4 | 5.7 | AC50 | 2020 | nM | CHEMBL_ACT_25151544 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| multidrug-resistant tuberculosis | 4 | MONDO:0005861 | EFO:0007381 |
| tuberculosis | 4 | MONDO:0018076 | MONDO:0018076 |
| pulmonary tuberculosis | 3 | MONDO:0006052 | EFO:1000049 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 28.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 16 |
| PHASE3 | 6 |
| Not specified | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04421495 | PHASE4 | UNKNOWN | Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China |
| NCT03568383 | PHASE3 | ACTIVE_NOT_RECRUITING | Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients |
| NCT05766267 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Short-course Regimens for the Treatment of Pulmonary Tuberculosis |
| NCT06081361 | PHASE3 | ACTIVE_NOT_RECRUITING | Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
| NCT06649721 | PHASE3 | ACTIVE_NOT_RECRUITING | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort |
| NCT01424670 | PHASE3 | COMPLETED | Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis |
| NCT02754765 | PHASE3 | COMPLETED | Evaluating Newly Approved Drugs for Multidrug-resistant TB |
| NCT02975570 | PHASE3 | WITHDRAWN | Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin |
| NCT03828201 | PHASE2 | ACTIVE_NOT_RECRUITING | Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB |
| NCT05556746 | PHASE2 | ACTIVE_NOT_RECRUITING | Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB |
| NCT00401271 | PHASE2 | COMPLETED | Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis |
| NCT00685360 | PHASE2 | COMPLETED | A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) |
| NCT01131351 | PHASE2 | TERMINATED | Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis |
| NCT01859923 | PHASE2 | COMPLETED | A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) |
| NCT02573350 | PHASE2 | COMPLETED | A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 |
| NCT02583048 | PHASE2 | COMPLETED | Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis |
| NCT02619994 | PHASE2 | COMPLETED | Treatment Shortening of MDR-TB Using Existing and New Drugs |
| NCT03141060 | PHASE1/PHASE2 | COMPLETED | Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB |
| NCT03959566 | PHASE2 | COMPLETED | PanACEA Sutezolid Dose-finding and Combination Evaluation |
| NCT04550832 | PHASE2 | COMPLETED | PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) |
| NCT05007821 | PHASE2 | COMPLETED | Linezolid Dosing Strategies in Drug-Resistant TB |
| NCT05221502 | PHASE2 | COMPLETED | Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB |
| NCT05382312 | PHASE2 | COMPLETED | Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis |
| NCT05926466 | PHASE2 | UNKNOWN | BTZ-043 Dose Evaluation in Combination and Selection |
| NCT06224036 | PHASE2 | UNKNOWN | Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis |
| NCT01856634 | PHASE1 | COMPLETED | Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis |
| NCT07198685 | Not specified | NOT_YET_RECRUITING | 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province |
| NCT00042289 | Not specified | COMPLETED | Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).